We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.
- Authors
Wang, Feng‐hua; Wang, Yun; Sun, Guo‐ping; Chen, Jian‐hua; Lin, Ying‐cheng; Liu, Wei; Zheng, Rong‐sheng; Chen, Jia; Zhang, He‐long; Lan, Hai‐tao; Qi, Jun; Liu, Yang‐qing; Deng, Yan‐ming; Zhao, Heng; Xiong, Jian‐ping; Xu, Qing; Jiang, Wen‐qi; Li, Yu‐hong
- Abstract
<bold>Background: </bold>Recombinant human lymphotoxin-α derivative (rhLTα-Da) is a lymphotoxin-α derivative that is missing 27 N-terminal amino acid residues. Previous studies indicated a benefit from the addition of rhLTα-Da to cisplatin-based treatment in patients with metastatic esophageal squamous cell carcinoma. The current study was conducted to evaluate the efficacy and safety of rhLTα-Da plus cisplatin and fluorouracil (PF) in patients with mESCC.<bold>Methods: </bold>Patients from 15 centers in China were randomly assigned (1:1:1) to 3 arms (arm A, PF plus 10 μg/m2 daily rhLTα-Da; arm B, PF plus 20 μg/m2 daily rhLTα-Da; arm C, PF alone). The primary endpoints included progression-free survival (PFS) and the confirmed overall response rate (ORR). An exploratory analysis was performed to evaluate the role of serum tumor necrosis factor receptor II (TNFR II) in predicting the efficacy of rhLTα-Da.<bold>Results: </bold>Between September 2010 and May 2013, 150 patients were enrolled. No significant differences in either PFS or ORR were observed between the 3 arms. However, in a small subset of patients who had low serum TNFR II levels, the median PFS was significantly longer for those in arm B than for these in other 2 arms (7.2 months [95% confidence interval, 5.1-8.6 months] for arm B vs 3.5 months [95% confidence interval, 1.7-5.5 months] for arm A [P = .022] and 4.0 months [95% confidence interval, 3.2-6.3 months] for arm C [P = .027]). The addition of rhLTα-Da significantly increased the incidence of chills (P < .001).<bold>Conclusions: </bold>rhLTα-Da combined with the PF regimen failed to improve PFS and ORR in patients with mESCC, except in a small subset that had low serum TNFR II concentrations. Cancer 2017;123:3986-94. © 2017 American Cancer Society.
- Subjects
CHINA; TREATMENT of esophageal cancer; SQUAMOUS cell carcinoma; CANCER treatment; TUMOR necrosis factors; CISPLATIN; FLUOROURACIL; DRUG efficacy; CLINICAL drug trials; THERAPEUTICS; ANTINEOPLASTIC agents; CELL receptors; COMPARATIVE studies; ESOPHAGEAL tumors; RESEARCH methodology; MEDICAL cooperation; PROGNOSIS; RECOMBINANT proteins; RESEARCH; STATISTICAL sampling; EVALUATION research; RANDOMIZED controlled trials; BLOOD
- Publication
Cancer (0008543X), 2017, Vol 123, Issue 20, p3986
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.30845